Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research and Development

Newly created role to oversee R&D organization and advance precision medicine portfolio vision CAMBRIDGE, Mass., Sept. 1, 2020 -- (Healthcare Sales & Marketing Network) -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company foc... Biopharmaceuticals, Personnel Blueprint Medicines, AYVAKIT, avapritinib, gastrointestinal stromal tumor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news